Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting

Abstract

Background: Obesity is a chronic disease with rising prevalence. Guidelines suggest medications for obesity management if lifestyle interventions do not lead to substantial weight loss. Randomized control trials have shown the efficacy of anti-obesity medications in inducing weight loss, but real-world data are lacking. Therefore, our study aims to evaluate anti-obesity medications’ effectiveness in reducing weight and improving cardiometabolic parameters and to assess their persistence in a real-world setting. Methods: A historical cohort study using routinely collected data from Clalit Health Services (CHS). We retrieved data on all CHS members aged ≥20 years who initiated anti-obesity medication (orlistat, liraglutide 3 mg, and lorcaserin) between 2018 and 2020. We assessed average weight loss and the percentage of patients that had lost ≥5% and ≥10% of their body weight at 3, 6, and 9 months and compared the effectiveness of these 3 medications. Results: We included 5,306 CHS members in our study; most (77.8%) were female, aged 40–59 years (52.4%). Treatment with liraglutide 3 mg and lorcaserin was associated with subsequent weight reduction. The average weight loss at 6 months was 5.6 kg (4.95–6.25, 95% confidence interval [CI]) with liraglutide 3 mg and 1.7 kg (1.2–2.2, 95% CI) with lorcaserin. There was no evidence that treatment with orlistat was associated with subsequent weight loss (−0.18 kg [−0.8 to 0.4, 95% CI]). At 6 months, 38% of the patients with orlistat, 43% with lorcaserin, and 51% with liraglutide 3 mg persisted with their treatments (P < 0.001). Conclusion: Liraglutide 3 mg was the primary medication associated with clinically significant weight loss and had the highest persistence rate in our real-world study.

Overview

Integrity signals

Registry

Crossref · 10.1093/fampra/cmac141

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. Ogden, 2015, Prevalence of obesity among adults and youth: United States, 2011–2014, NCHS Data Brief, 219, 1

Cited by

See all 12

Metadata

Authors
Leventhal-Perek, S., Shani, M., & Schonmann, Y.
Affiliations
  • Tel Aviv University (IL)
  • Ben-Gurion University of the Negev (IL)
Corresponding author
Leventhal-Perek, Sharon
Venue
Family Practice
Published
2022-12-08
Volume
40
Issue
5-6
Pages
629-637
ISSN
  • 0263-2136 (ISSN-L)
  • 1460-2229
OpenAlex
W4310960180
Cited by
11
References
36
Citations by year
2026: 1 · 2025: 5 · 2024: 5
FWCI
1.50
Type
journal article
Language
en
Open access
closed
Locations
  • Family Practice (publishedVersion)
  • PubMed (publishedVersion)
Funders
departmental resources
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
anti-obesity drugs, obesity, weight loss, lorcaserin, orlistat, treatment persistence, cardiometabolic parameters, primary care, real-world effectiveness
MeSH terms
Liraglutide, Orlistat, Benzazepines, Female, Humans, Male, Primary Health Care, Cohort Studies, Weight Loss, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting. https://app.cochat.ai/papers/10.1093/fampra/cmac141
The paper
Leventhal-Perek, S., Shani, M., & Schonmann, Y. (2023). Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting. Family Practice. https://doi.org/10.1093/fampra/cmac141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.